OpenBiome Webinar
On December 14, 2022, the OpenBiome team held a live webinar to discuss a new FDA guidance governing the use of FMT and approval of REBYOTA™. Key takeaways and an FAQ are shared below.

Key Takeaways
The U.S. FDA recently announced final guidance for the use of FMT in the treatment of recurrent C. difficile infection (rCDI) not responsive to standard therapies.
The U.S. FDA approved the first fecal microbiota product for the treatment of rCDI in adults marking a major milestone for the field and a huge win for patients.
OpenBiome will continue distributing FMT for patients suffering from rCDI not responsive to standard therapies.
Frequently Asked Questions
